Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.

Article  PubMed  Google Scholar 

Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–54.

Article  PubMed  CAS  Google Scholar 

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955–62.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gay F, Bertuglia G, Mina R. A rational approach to functional high-risk myeloma. Hematol Am Soc Hematol Educ Program. 2023;2023:433–42.

Article  Google Scholar 

Bygrave C, Pawlyn C, Davies F, Craig Z, Cairns D, Hockaday A, et al. Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. Br J Haematol. 2021;193:551–5.

Article  PubMed  CAS  Google Scholar 

Spencer A, Mollee P, Blacklock HA, Harison S, Quach H, Ho JP, et al. Real-world outcome for newly diagnosed patients with functional high-risk myeloma—a myeloma and related diseases registry analysis. Blood. 2019;134(1):269.

Article  Google Scholar 

Soekojo CY, Chung TH, Furqan MS, Chug WJ. Identifying the genomic profile of functional high-risk multiple myeloma patients. Blood. 2020;136(Supplement 1):51–2.

Article  Google Scholar 

Soekojo CY, Chung TH, Furqan MS, Chng WJ. Genomic characterization of functional high-risk multiple myeloma patients. Blood Cancer J. 2022;12:24.

Article  PubMed  PubMed Central  Google Scholar 

Zaccaria GM, Bertamini L, Petrucci MT, Offidani M, Corradini P, Capra A, et al. Development and validation of a simplified score to predict early relapse in newly diagnosed multiple myeloma in a pooled dataset of 2,190 patients. Clin Cancer Res. 2021;27:3695–703.

Article  PubMed  CAS  Google Scholar 

Beksac M, Iacobelli S, Koster L, Blaise D, Cornelissen JJ, Reményi P, et al. A novel early relapse prediction score based on age, ISS and disease status at the time of transplant in patients with newly diagnosed multiple myeloma. A study of the EBMT chronic malignancies working party. Blood. 2021;138(1):3937.

Article  Google Scholar 

Dhakal B, D’Souza A, Callander N, Chhabra S, Fraser R, Davila O, et al. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Br J Haematol. 2020;191:442–52.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Beksac M, Iacobelli S, Koster L, Cornelissen J, Griskevicius L, Rabin NK, et al. An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT. Bone Marrow Transplant. 2023;58:916–23.

Article  PubMed  CAS  Google Scholar 

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, EHA Guidelines Committee ESMO Guidelines Committee, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309–22.

Article  PubMed  CAS  Google Scholar 

Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37:1228–63.

Article  PubMed  Google Scholar 

Iida S, Ishida T, Murakami H, Ozaki S, Abe M, Hata H, et al. JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM). Int J Hematol. 2019;109:509–38.

Article  PubMed  Google Scholar 

Puig N, Hungria VTM, Chari A, Davies FE, Cook G, Hájek R, et al. Global treatment standard in multiple myeloma remains Elusive: updated results from the INSIGHT MM global, prospective. Observ Study Blood. 2022;140(Supplement 1):4269–72.

Google Scholar 

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.

Article  PubMed  Google Scholar 

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

Article  PubMed  CAS  Google Scholar 

Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, et al. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia. 2018;32:986–95.

Article  PubMed  CAS  Google Scholar 

Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Migkou M, Gika D, et al. Early relapse after autologous transplant is associated with very poor survival and identifies an ultra-high-risk group of patients with myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:445–52.

Article  PubMed  Google Scholar 

Wang YT, Chu B, Zhou TG, Lu MQ, Shi L, Gao S, et al. Clinical and genomic characterization of Chinese patients with functional high-risk multiple myeloma: a real-world validation study. Front Oncol. 2023;13:1110693.

Article  PubMed  PubMed Central  Google Scholar 

Suzuki K, Shimazu Y, Minakata D, Ikeda T, Takahashi H, Tsukada N, Working group of the Japan Society for Transplantation and Cellular Therapy, et al. Efficacy of autologous stem cell transplantation for myeloma patients with suboptimal response: a multicenter retrospective analysis. Transplant Cell Ther. 2023;29:688.e1-688.e13.

Article  PubMed  Google Scholar 

Wang Y, Xu J, Xu B, Li P, Yang Y, Wang W, et al. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: the faster, the worse. Cancer. 2023;129:1005–16.

Article  PubMed  CAS  Google Scholar 

Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:1582–96.

Article  PubMed  CAS  Google Scholar 

Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29–38.

Article  PubMed  CAS  Google Scholar 

Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022;40:2901–12.

Article  PubMed  CAS  Google Scholar 

Sonneveld P, Dimopoulos MA, Boccadoro M, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301–13.

Article  PubMed  CAS  Google Scholar 

Leypoldt LB, Tichy D, Besemer B, Hänel M, Raab MS, Mann C, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol. 2024;42:26–37.

Article  PubMed  CAS  Google Scholar 

Shimazu Y, Kanda J, Suzuki K, Wada A, Kikuchi T, Ikeda T, et al. The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation. Cancer Sci. 2024;115:2384–95.

Article  PubMed  PubMed Central  CAS